Please find attached press release for the quarter and financial year ended March 31, 2026.
PGHL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Procter & Gamble Health Ltd reported strong Q4 FY26 results with sales of ₹365 crores, up 20% year-over-year, and PAT of ₹95 crores, up 55%. For the full year ending March 2026, the company achieved sales of ₹1,385 crores (up 16%) and PAT of ₹327 crores (up 30%) compared to the comparable 12-month period last year. The company noted it changed its fiscal year from July-June to April-March, making results comparable to the April 2024-March 2025 period. Management highlighted investment in product innovations including Livogen Iron Gummies and Neurobion Nerve Pain Relief Cream. The board recommended a final dividend of ₹45 per share, taking total dividend payout to ₹205 per share including the interim dividend already paid.
Strong double-digit revenue and profit growth with robust PAT expansion signals operational efficiency gains. The increased dividend payout is positive for income-focused shareholders, and the new product launches indicate continued focus on portfolio expansion.